Just as certain COVID-19 vaccines may be better suited for certain groups of people, certain COVID-19 vaccine stocks may be better suited for different investing styles. So, of the six leaders or potential leaders in the U.S. COVID-19 vaccine space right now, which may be the best pick for conservative investors and which may be the best pick for aggressive…
Among the four biotech stocks that may be worth considering this month highlighted in today’s article is a company focused on developing genetic therapies with the potential to restore, improve and preserve high-acuity physiological hearing for people living with certain forms of disabling hearing loss. For more on this company and the other three biotech stocks featured, CLICK HERE.
“The company highlighted in today’s article “helps its customers to find the exceedingly rare cells/antibodies needed to fight cancer, inflammation etc. Basically, to find the needle in the haystack” – and as it operates in a high-growth and rapidly expanding area of biotech, the author believes that this digital cell biology company is a solid candidate for high-growth/high-risk portfolios. For…
“It’s a small cap, a billion-dollar company, 100% revenue growth, and it’s small and it’s unknown,” says the author of today’s article of the pharmaceutical marketing company he highlights, which is disrupting the way that drugs are traditionally sold to physicians – and has become a multi-bagger stock in the process. For more on this “under-the-radar pic for investors who…have…
While large-cap stocks receive more attention from analysts and more investment, the author of today’s article reminds the reader that “small caps, over time, outperform their larger peers.” With that, she proceeds to highlight three small-cap stocks that are showing strong technical performance – including, in the biotech arena, a genetic-testing specialist. For more, CLICK HERE.
What’s the best proxy for the trends that can help you make money? The answer may be the 50-day moving average, which the author of today’s article advises “is in the goldilocks zone of not being too short or too long.” Using the example of a potentially game-changing stock from the green energy sector, he outlines how traders can use…
“To me, this is the biggest contrarian bet you can make today. If you’ve got the guts to make the trade, it could lead to massive upside from here,” says the author of today’s article in regards to the investment opportunity he outlines – one that involves an investment that, being cheap, hated and in the start of an uptrend,…
As the biotech sector has received increased investor focus over the past year amid the COVID-19 pandemic, the author of today’s article notes that “Even the smaller and lesser known are being seen now as having immense potential; Many of these companies are working tirelessly toward new drug developments and eyeing larger collaborations.” With that, she proceeds to highlight three…
Trillium Therapeutics surged 1,330% last year – and as an immuno-oncology company, its performance had nothing to do with COVID-19 related catalysts. Moreover, its 2020 run may have just been the beginning, as the company’s cancer-fighting candidates – which it hopes will ultimately replace chemotherapy as the dominant type of cancer treatment – are, as today’s article explains, currently in…
“These four look like solid picks for more aggressive growth investors as they have significant catalysts that can drive growth for the rest of 2021 and beyond,” says the author of today’s article in regards to the four stocks he proceeds to highlight, each of which is a top growth stock call for 2021 from Jefferies. For these four stocks…